Excess coronary artery disease risk in South Asian immigrants: Can dysfunctional high-density lipoprotein explain increased risk?

Vascular Health and Risk Management

Volumn 4, Issue 5, 2008, Pages 953-961

  Dodani, Sunita ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cardiovascular risk; Coronary heart disease; High density lipoprotein; South Asian immigrants

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASIAN; CARDIOVASCULAR RISK; CAUCASIAN; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ENZYME INHIBITION; ETHNICITY; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; IMMIGRANT; LIPOPROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT;

APOLIPOPROTEIN A-I; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; EMIGRANTS AND IMMIGRANTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; METABOLIC SYNDROME X; POLYMORPHISM, GENETIC; RISK FACTORS; UNITED STATES;

EID: 56849088667     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Anand SS, Yusuf S, Vuksart V, et al. 2000. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet, 356:279-84.
2. Ansell BJ, Fonarow GC, Fogelman AM. 2005. High-density lipoprotein function recent advances. J Am Coll Cardiol, 46:1792-8.
3. Ansell BJ, Fonarow GC, Fogelman AM. 2006. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep, 8:405-11.
4. Ansell BJ, Fonarow GC, Navab M, et al. 2007. Modifying the anti-inflammatory effects of high-density lipoprotein. Curr Atheroscler Rep, 9:57-63.
5. Ansell BJ, Navab N, Hama S. 2003. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by Simvastatin treatment. Circulation, 108:2751-6.
6. Barter PJ, Baker PW, Rye KA. 2002. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol, 13:285-8.
7. Bedi US, Singh S, Syed A, et al. 2006. Coronary artery disease in South Asians: an emerging risk group. Cardiol Rev, 14:74-80.
8. Bhatnagar D, Anand IS, Durrington PN, et al. 2005. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet, 345:405-9.
9. Bhopal R, Fischbacher C, Vartiainen E. 2005. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health, 27:93-100.
10. Bhopal R. 2002. Epidemic of cardiovascular disease in South Asians. BMJ, 16:324.
11. Boekholdt SM, Souverein OW, Tanck MW, et al. 2006. Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. Clin Genet, 69:263-70.
12. Calabresi L, Franceschini G. 1997. High density lipoprotein and coronary heart disease: Insights from mutations leading to low high density lipoprotein. Curr Opin Lipidol, 8:219-24.
13. Castelli WP, Garrison RJ, Wilson PW, et al. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA, 256:2835-8.
14. Chhabra S, Narang R, Lakshmy R, et al. 2005. APO A-I 75 G to A substitution associated with severe forms of CAD, lower levels of HDL and Apo A-1 among Northern Indians. Disease Markers, 21:169-74.
15. D'Agostino RB Sr, Grundy S, Sullivan LM, et al. 2001. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA, 286:180-7.
16. Dodani S, Dong Y, Zhu H, et al. 2008a. Can novel Apo A-I polymorphisms be responsible for low HDL in South Asians. Indian J Hum Genetics, In press.
17. Dodani S, Kaur R, Mohammad N, et al. 2008b. Can dysfunctional HDL explain excess risk of coronary artery diseases in South Asian immigrants? Int J Cardiol, Feb 4. Epub ahead of print.
18. Downs JR, Clearfield M, Weis S, et al. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279:1615-22.
19. Enas EA, Garg A, Davidson MA, et al. 1996. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J, 48:343-53.
20. Enas EA, Yusuf S, Mehta J, et al. 1992. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol, 70:945-9.
21. Enas EA. 2000. Coronary artery disease epidemic in Indians: a cause for alarm and call for action. J Indian Med Assoc, 98:694-5.
22. [NCEP ATP III] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285:2486-97.
23. Fogelman AM. 2004. When good cholesterol goes bad. Nat Med, 10:902-3.
24. Forouhi N, McKeigue P. 1997. How far can risk factors account for excess coronary mortality in South Asians? Can J Cardiol, 13:47B.
25. Forouhi NG, Sattar N, Tillin T, et al. 2006. Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies. Diabetologia, 49:2580-8.
26. Forouhi NG, Sattar N. 2006. CVD risk factors and ethnicity - a homogeneous relationship? Atheroscler, 7:11-9.
27. Frank PG Marcel YL. 2000. Apolipoprotein A-I: structure - function relationships. J Lipid Res, 41:853-72.
28. Gordon DJ, Probstfield JL, Garrison RJ, et al. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79:8-15.
29. Goyal A, Yusuf S. 2006. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res, 124:235-44.
30. Graham A, Hassall DJ, Rafique S. 1997. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis, 135:193-204
31. Grundy SM. 2002. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation, 105:2696-8.
32. Guettier JM, Georgopoulos A, Tsai MY, et al. 2005. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab, 90:1705-11.
33. [HPS] Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20,536 high-risk individuaW a randomized placebo-controlled trial. Lancet, 360:7-22.
34. Hoogeveen RC, Gambhir JK, Gambhir DS, et al. 2001. Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res, 42:631-8.
35. Hovingh GK, Brownlie A, Bisoendial RJ, et al. 2004. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol, 44:1429-35.
36. Islam MS, Raitakari OT, Juonala M, et al. 2005. Apolipoprotein A-I/C-III/ A-IV SstI and apolipoprotein B XbaI polymorphisms and their association with carotid artery intima-media thickness in the Finnish population. The Cardiovascular Risk in Young Finnish Study. Atherosclerosis, 180:79-86.
37. Jadhav UM, Kadam NN. 2004. Apolipoproteins: correlation with carotid intima media thickness and coronary artery disease. J Assoc Physicians India, 52:370-5.
38. Joshi P, Islam S, Pais P, et al. 2007. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA, 297:286-94.
39. Kalhan R, Puthawala K, Agarwal S, et al. 2001. Altered lipid profile, leptin, insulin, and anthropometry in offspring of South Asian immigrants in the United States. Metabolism, 50:1197-202.
40. Karathanasis SK. 1985. Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes. Proc Natl Acad Sci USA, 82:6374-8.
41. Klatsky AL, Tekawa I, Armstrong MA, et al. 1994. The risk of hospitalization for ischemic heart disease among Asian Americans in northern California. Am J Public Health, 84:1672-5.
42. Kobayashi KY, Yanagi H, Fukayama H, et al. 1998. Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey. Hum Mol Genet, 8:331-6.
43. Koistinen MJ, Huikuri HV, Korhonen UR, et al. 1994. Asymptomatic coronary artery disease in diabetes: relation to common risk factors, lipoproteins, apolipoproteins and apo E polymorphism. Acta Diabetol, 31:210-14.
44. Kottke TE, Thomas RJ, Lopez-Jimenez F, et al. 2006. CardioVision 2020: Program acceptance and progress after 4 years. Am J Prev Med, 30:137-43.
45. Kumar AP, Reynolds WF. 2005. Statins down regulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun, 331:442-51.
46. Luepker RV, Arnett DK, Jacobs JR, et al. 2006. Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med, 119:42-9.
47. Lusis AJ, Fogelman AM, Fonarow GC, et al. 2004. Genetic basis of atherosclerosis: part II: clinical implications. Circulation, 110:2066-71.
48. Mackness MI, Arrol S, Abbott C, et al. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 104:129-35.
49. Marathe GK, Zimmerman GA, McIntyre TM. 2003. Platelet-activating factor acetylhydrolase, and not paraoxonase-1 is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem, 278:3937-47.
50. McGovern PG, Pankow JS, Shahar E, et al. 1996. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med, 334:884-90.
51. Mohan V, Deepa R, Shanthi Rani SS, et al. 2001. Chennai Urban Population Study (CUPS No.5). Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India. The Chennai Urban Population Study (CUPS No. 5). J Am Coll Cardiol, 38:682-7.
52. Moll PP, Michel VV, Weidman WH, et al. 1989. Genetic determination of plasma apolipoprotein A-I in a population based sample. Am J Hum Genet, 44:24-39.
53. Navab M, Anantharamaiah GM, Reddy ST, et al. 2004. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol, 15:645-9.
54. Navab M, Anantharamaiah GM, Reddy ST, et al. 2006. Mechanisms of disease: proatherogenic HDL - an evolving field. Nat Clin Pract Endocrinol Metab, 2:504-11.
55. Navab M, Ananthramaiah GM, Reddy ST. 2005. The double jeopardy of HDL. Ann Med, 37:173-8.
56. Navab M, Berliner JA, Subbanagounder G. 2001. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol, 21:880.
57. Navab M, Hama SY, Anantharamaiah GM, et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res, 41:1495-508.
58. Navab M, Hama SY, Cooke CJ, et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res, 41:1481-94.
59. Navab M, Hama SY, Hough GP, et al. 2001. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res, 42:1308-17.
60. Nordlie MA, Wold LE, Kloner RA. 2005. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol, 39:667-9.
61. Perez-Mendez O, Bruckert E, Franceschini G, et al. 2000. Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis, 148:317.
62. Petersen S, Peto V, Rayner M. 2004. Coronary heart disease statistics, British Heart Foundation, London (2004) [online]. Accessed on February 10, 2008. URL: http://www.heartstats.org/datapage.asp?id=1652.
63. Pulkkinen A, Viitanen L, Kareinen A, et al. 2000. MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease. Diabetes Care, 23:791-5.
64. Raji A, Gerhard H, Warren M. 2004. Insulin resistance and vascular dysfunction in non diabetic Asian Indians. J Clin Endocrinol Metab, 9:3965-72.
65. Remaley AT, Stonik JA, Demosky SJ, et al. 2000. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun, 280:818-23.
66. Sacks FM, Pfeffer MA, Moye LA, et al. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 335:1001-9.
67. Sadaf A, Siddiqui S, Lestringant GG, et al. 2002. Apolipoprotein AI promoter variant in blood pressure determination. Clin Genet, 61:314-16.
68. [SSSG] Scandinavian Simvastatin Survival Group Study. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344:1383-9.
69. Shepherd J, Cobbe SM, Ford I, et al. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med, 333:1350-1.
70. Stampfer MJ, Sacks FM, Salvini S, et al. 1991. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med, 325:373-81.
71. Takahashi Y, Smith JD. 1999. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc Natl Acad Sci USA, 96:11358-63.
72. Tillin T, Forouhi N, Johnston DG. 2005. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study. Diabetologia, 48:649-56.
73. Tulenko TN, Sumner AE. 2002. The physiology of lipoproteins. J Nucl Cardiol, 9:638-49.
74. Uppaluri CR. 2002. Heart disease and its related risk factors in Asian Indians. Ethn and Dis, 12:45-53.
75. Wang XL, Liu SX, McCredie RM, et al. 1996. Polymorphisms at the 5 prime-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest, 98:372-7.
76. Watson KE, Ansell BJ, Watson AD, et al. 2007. HDL Function as a target of lipid-modifying therapy. Rev Cardiovasc Med, 8:1-8.
77. Williams B. 1995. Westernized Asians and cardiovascular disease: nature or nurture? Lancet, 345:401-2.
78. Williams DL, Connelly MA, Temel RE, et al. 1999. Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipidol, 10:329-39.
79. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. 2003. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thomb Vasc Biol, 23:712-19.
80. Zheng L, Nukuna B, Brennan ML, et al. 2004. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest, 114:529-41.